{"id":"W3027723947","doi":"10.1016/j.annonc.2020.03.281","title":"181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Oncolytics Biotech; Astellas Pharma; Eisai; Bayer HealthCare; Seagen; MacroGenics; Pfizer; HCA Healthcare; Incyte; Moderna; Puma Biotechnology; Agios Pharmaceuticals; Queen Mary University of London; Clovis Oncology; Mylan; TG Therapeutics; Baxalta; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Array BioPharma; Daiichi Sankyo Europe; Servier; Gilead Sciences; GlaxoSmithKline; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; Everolimus; Clinical endpoint; Breast cancer; Exemestane; Progression-free survival; Cancer; Chemotherapy; Clinical trial; Tamoxifen","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002208459,0.0002333887,0.0005001518,0.0001520208,0.0001336484,0.0002320817,0.0001799101,0.0002503034,0.001270564],"category_scores_gemma":[0.0003319504,0.0001259977,0.0002840775,0.0001971487,0.0001413678,0.0002218748,0.0001217535,0.0005990324,0.0002194914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002451286,"about_ca_system_score_gemma":0.0002441827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003269908,"about_ca_topic_score_gemma":0.001225753,"domain_scores_codex":[0.9999,0.00002968512,0.000008858989,0.00001877563,0.00001360679,0.00002916164],"domain_scores_gemma":[0.9999188,0.00001769755,0.00001541388,0.000004401707,0.000003763019,0.0000398704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2436888,0.005210422,0.1060166,0.0009835768,0.001701941,0.005356717,0.0002828837,0.002720551,0.0814371,0.0007072954,0.007828289,0.5440659],"study_design_scores_gemma":[0.05702994,0.2161718,0.6207617,0.000342821,0.003829858,0.02526022,0.0003669867,0.01003846,0.02829717,0.001153313,0.03664231,0.0001053437],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9888232,0.007463718,0.0002819192,0.0003608053,0.0001038115,0.00005689543,0.0001237491,0.00004562103,0.002740459],"genre_scores_gemma":[0.9974406,0.001308074,0.00023038,0.0001509214,0.00005819156,0.00002223475,0.0001366586,0.000003244049,0.0006496524],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.001270564,"threshold_uncertainty_score":0.004250467,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04301449619106178,"score_gpt":0.3380875263296249,"score_spread":0.2950730301385631,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}